Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $1.7 million.

  • Lifecore Biomedical, Inc. \De\'s Change in Receivables rose 20072.46% to $1.7 million in Q2 2025 from the same period last year, while for May 2025 it was $2.3 million, marking a year-over-year decrease of 3067.73%. This contributed to the annual value of $2.3 million for FY2025, which is 3067.73% down from last year.
  • According to the latest figures from Q2 2025, Lifecore Biomedical, Inc. \De\'s Change in Receivables is $1.7 million, which was up 20072.46% from $1.3 million recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s 5-year Change in Receivables high stood at $16.1 million for Q4 2023, and its period low was -$11.0 million during Q2 2023.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Change in Receivables had a median value of $561000.0 in 2021 and averaged -$244000.0.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Change in Receivables skyrocketed by 88207.55% in 2021 and then crashed by 69293.44% in 2023.
  • Lifecore Biomedical, Inc. \De\'s Change in Receivables (Quarter) stood at $3.5 million in 2021, then crashed by 251.77% to -$5.2 million in 2022, then surged by 407.0% to $16.1 million in 2023, then plummeted by 66.52% to $5.4 million in 2024, then tumbled by 69.21% to $1.7 million in 2025.
  • Its Change in Receivables stands at $1.7 million for Q2 2025, versus $1.3 million for Q1 2025 and $5.4 million for Q4 2024.